Drug Profile
Research programme: radioimmunoconjugate therapies - Heidelberg Pharma/Telix Pharmaceuticals
Latest Information Update: 28 Feb 2021
Price :
$50
*
At a glance
- Originator Telix Pharmaceuticals; WILEX AG
- Developer Telix Pharmaceuticals
- Class Antineoplastics; Immunoconjugates; Monoclonal antibodies; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Feb 2021 No recent reports of development identified for research development in Cancer in Australia (Parenteral)
- 16 Jan 2017 Early research in Cancer in Australia (Parenteral) (Telix website, May 2017)
- 16 Jan 2017 WILEX licenses girentuximab to Telix Pharmaceuticals for use with therapeutic radionuclides